---
title: "Chrissy Teigen Joins Sanofi Campaign for Early Diabetes Testing"
description: "Chrissy Teigen has become the face of Sanofi's diabetes campaign, \"Screen for Type 1,\" aimed at promoting early screening for type 1 diabetes. Teigen's involvement follows her son Miles' diagnosis at "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/236763991.md"
published_at: "2025-04-21T10:00:00.000Z"
---

# Chrissy Teigen Joins Sanofi Campaign for Early Diabetes Testing

> Chrissy Teigen has become the face of Sanofi's diabetes campaign, "Screen for Type 1," aimed at promoting early screening for type 1 diabetes. Teigen's involvement follows her son Miles' diagnosis at age 6, highlighting the need for proactive health measures. Sanofi's Nadia Fontaine emphasized the importance of early detection to prevent serious complications. Additionally, Sanofi has committed $18 million to enhance diversity in clinical trials through partnerships with historically Black medical schools, aiming to improve healthcare representation and equity.

Chrissy Teigin is the new face of Sanofi’s diabetes campaign.1 The educational campaign is called Screen for Type 1, and it is focused on providing information about the importance of screening for the disease. According to Sanofi, blood tests can identify the condition before symptoms have begun to present themselves.

Teigen joined the campaign after her son Miles was diagnosed with the disease at just 6 years old. According to her, Miles briefly ended up in the hospital, and she hopes that by sharing her experiences as a mother that she can help other families avoid this.

In a press release, Teigen said, “Our family knew nothing about type 1 diabetes prior to 2024–and when I say nothing, I mean absolutely nothing. We were confused and scared when Miles was first diagnosed. Miles is a warrior–a type 1 diabetes warrior–and we are learning together every day how to help him manage this disease, but there is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!"

In the same press release, Nadia Fontaine, head of US autoimmune type 1 diabetes franchise for Sanofi, added, “It's unacceptable that many people are still finding out about a type 1 diabetes diagnosis only when serious complications arise. We're energized to partner with Chrissy Teigen on the Screen For Type 1 movement and believe her story will strongly resonate with families and underscore the importance of early risk detection."

This is Sanofi’s latest endeavor to improve patient conditions. In October of last year, the company announced that it would be contributing $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine as part of the company’s goal of improving diversity in clinical trials.2

In a press release issued at the time, Sanofi’s senior vice president and global head of clinical trials and operations Lionel Bascles said, “At Sanofi, our mission is to chase the miracles of science to improve people's lives, and this means all people's lives, regardless of their race or ethnicity. By partnering with these three esteemed Historically Black College and University medical schools, we hope to facilitate new inroads to communities that have been underrepresented in healthcare for far too long. Increasing diversity and inclusion is essential to the research and development of medicines and vaccines for people of all backgrounds."

Valerie Montgomery Rice, MD, FACOG, president and CEO of the Morehouse School of Medicine added, “Morehouse School of Medicine is exceptionally grateful to Sanofi for this investment in our clinical study diversity Center of Excellence. We look forward to a robust partnership as we work to increase diversity in clinical studies and develop advanced opportunities for researchers, leading to greater health equity. More diversity in clinical studies will ensure traditionally underserved populations receive the very latest cutting-edge therapeutic innovations."

## Sources

1.  Chrissy Teigen - Author, Entrepreneur, Mom to Young Son with Type 1 Diabetes - Joins Sanofi's Screen For Type 1 Movement. *Sanofi*. April 15, 2025. https://www.prnewswire.com/news-releases/chrissy-teigen--author-entrepreneur-mom-to-young-son-with-type-1-diabetes--joins-sanofis-screen-for-type-1-movement-302426703.html
2.  Sanofi Commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to Increase Diversity in Clinical Studies. *Sanofi*. October 16, 2024. Accessed April 18, 2025. https://www.prnewswire.com/news-releases/sanofi-commits-18-million-to-howard-university-college-of-medicine-meharry-medical-college-and-morehouse-school-of-medicine-to-increase-diversity-in-clinical-studies-302276979.html

### Related Stocks

- [SNYNF.US - Sanofi](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 德克薩斯州起訴賽諾菲，指控其涉嫌通過'賄賂'醫療服務提供者來增加藥品處方量 | 德克薩斯州檢察長肯·帕克斯頓已對賽諾菲提起訴訟，指控該公司賄賂醫療服務提供者以推廣其藥物。訴訟稱，賽諾菲的項目違反了德克薩斯州醫療保健計劃欺詐預防法。帕克斯頓尋求超過一百萬美元的經濟賠償和對進一步非法行為的禁令。這是繼對賽諾菲及其他公司因類 | [Link](https://longbridge.com/en/news/276391061.md) |
| Grok 疑生成性深偽影像惹議 被歐盟監管機構盯上 | 愛爾蘭資料保護委員會已對社羣平台 X 的 AI 聊天機器人 Grok 展開正式調查，關注其處理個人資料及生成有害性影像的方式。調查旨在判斷 X 是否遵守 GDPR 規定，可能面臨高達全球營收 4% 的罰款。Grok 因生成近乎裸露的真實人物 | [Link](https://longbridge.com/en/news/276115264.md) |
| 俄烏代表在日內瓦繼續第 2 天和平談判 | 烏克蘭和俄羅斯的談判代表在日內瓦繼續進行和平會談。美國特使魏科夫對衝突結束表示樂觀，稱川普政府在推動和談上取得進展。烏克蘭國家安全秘書烏梅洛夫感謝美國的調解，並與歐洲盟國討論談判結果。儘管澤倫斯基準備達成協議，但對俄羅斯的和平意圖表示懷疑， | [Link](https://longbridge.com/en/news/276301661.md) |
| 富衞香港：25 年上半年新業務年度化保費按年升 90% | 富衞香港公佈 2025 年上半年新業務年度化保費按年升 90%，優於行業平均升幅 39%。新業務首年保費增長 128%，排名全港第二。各分銷渠道均實現雙位數增長，專屬代理人渠道升 69%，銀行保險渠道升 53%，經紀渠道升 291%，網上及 | [Link](https://longbridge.com/en/news/276418423.md) |
| 石四藥 (2005) 發盈警料去年盈利倒退 45 至 60% | 石四藥集團發盈警，預期截至去年底止年度股東應佔溢利按年下跌 45 至 60%；2024 年度錄得股東應佔溢利 10.61 億港元。 | [Link](https://longbridge.com/en/news/276431030.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
